# Supplementary appendix

Table 1: Statistical fit of alternative PFS and OS extrapolations

|  |  |  |
| --- | --- | --- |
| Extrapolation | One-piece | Two-piece\* |
| AIC | BIC | AIC | BIC |
| **OS for pembrolizumab** |
| Exponential | 212.6 | 214.5 | 74.1 | 75.8 |
| Weibull | 212.7 | 216.5 | 75.9 | 79.1 |
| Log-normal | 210.9 | 214.7 | 75.4 | 78.7 |
| Log-logistic | 212.1 | 215.8 | 75.8 | 79.1 |
| Gompertz | 210.5 | 214.3 | 75.7 | 79.0 |
| Generalized gamma | 211.9 | 217.6 | 73.7 | 78.6 |
| **OS for chemotherapy** |
| Exponential | 1275.1 | 1278.6 | NA | NA |
| Weibull | 1266.1 | 1273.1 | NA | NA |
| Log-normal | 1257.9 | 1265.0 | NA | NA |
| Log-logistic | 1258.7 | 1265.7 | NA | NA |
| Gompertz | 1274.9 | 1281.9 | NA | NA |
| Generalized gamma | 1259.9 | 1270.4 | NA | NA |
| **PFS for pembrolizumab** |
| Exponential | 281.0 | 282.9 | 164.8 | 166.4 |
| Weibull | 276.8 | 280.6 | 163.2 | 166.4 |
| Log-normal | 271.8 | 275.6 | 162.9 | 166.1 |
| Log-logistic | 274.2 | 278.0 | 163.0 | 166.2 |
| Gompertz | 270.8 | 274.6 | 163.6 | 166.8 |
| Generalized gamma | 266.8 | 272.5 | 164.9 | 169.7 |
| **\*** For OS Kaplan-Meier data was used until week 40, for PFS Kaplan-Meier data was used until week 10**Key:** AIC, Akaike information criterion; BIC, Bayesian information criterion; KM, Kaplan–Meier; OS, overall survival; PFS, progression free survival. |

Figure 1: Visual fits of alternative PFS and OS extrapolations

1. Overall survival for pembrolizumab using one-piece models



**Note:** The plot includes all curves fitted to all KM data, including clinically implausible selections.

1. Overall survival for pembrolizumab using two-piece models



**Note:** The plot includes all curves fitted to all KM data, including clinically implausible selections.

1. Overall survival for chemotherapy using one-piece models



**Note:** The plot includes all curves fitted to all KM data, including clinically implausible selections.

1. Progression-free survival for pembrolizumab using a one-piece model



**Note:** The plot includes all curves fitted to all KM data, including clinically implausible selections.

1. Progression-free survival for pembrolizumab using a two-piece model



**Note:** The plot includes all curves fitted to all KM data, including clinically implausible selections.